News

DG Enterprise to take the lead
Enlarge image

PoliticsEU

DG Enterprise to take the lead

15.09.2014 - Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

The directorate-general DG Health had previously taken over the lead role from DG Enterprise & Industry. Juncker has now stated that the units will be moved back from DG Health to DG Enterprise & Industry under the newly created responsibility for the Internal Market, Industry, Entrepreneurship and SMEs of Commissioner of Elzbieta Bienkowska. DG Enterprise will take the lead in promoting the pharmaceutical industry and health policy. 

More specifically, units SANCO B2 (Health Technology and Cosmetics), SANCO D5 (Medicinal Products – Authorisations, EMA) and SANCO D6 (Medical Products – Quality, Safety and Efficacy) will be moved.

DG Health and Food Safety headed by Vytenis Andriukaitis will have responsibility for food safety watchdog EFSA, the European Centre for Diseases Prevention and Control (ECDC) as well as the European Plant Varieties Office. Commissioner Phil Hogan will be responsible for Agriculture & Rural Development and Carlos Moedas will head Research and Innovation.

During the presentation of his new team, Juncker took a strong stance towards the industry: “We must make use of public funds available at Union level to stimulate private investment in the real economy" he said promising smarter investment, more focus, less regulation and more flexibility in funding. “We must not stifle innovation and competitiveness with too prescriptive and too detailed regulations,” said Juncker, ”notably when it comes to SMEs.”

© european-biotechnology-news.com/jc+tg

http://www.european-biotechnology-news.com/news/news/2014-03/juncker-announces-changes-in-the-medical-technology-industry.html

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

BusinessDenmark

04.09.2014 After their arthritis product’s Phase IIb failure, Novo Nordisk A/S is pulling out of all research and development activities within inflammatory disorders.

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/news/pos/2.html

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.09 CHF12.50%
  • PAION2.99 EUR11.15%
  • CO.DON3.00 EUR5.63%

FLOP

  • 4SC1.09 EUR-6.03%
  • STRATEC BIOMEDICAL39.80 EUR-3.40%
  • ADDEX3.22 CHF-3.30%

TOP

  • SANTHERA91.65 CHF43.0%
  • CO.DON3.00 EUR26.1%
  • PAION2.99 EUR20.1%

FLOP

  • EVOTEC3.07 EUR-18.1%
  • 4SC1.09 EUR-18.0%
  • MEDIGENE4.06 EUR-14.0%

TOP

  • SANTHERA91.65 CHF1987.7%
  • CO.DON3.00 EUR244.8%
  • PAION2.99 EUR187.5%

FLOP

  • CYTOS0.24 CHF-94.0%
  • 4SC1.09 EUR-43.2%
  • MERCK KGAA67.58 EUR-41.3%

No liability assumed, Date: 15.09.2014